Login to Your Account



Companies Forge Ahead

PRC Awaits U.S./EU/WHO Biosimilars Guidance

By Cornelia Zou
Contributing Writer

Monday, October 21, 2013
HONG KONG – Defying all expectations of an early announcement, biosimilar developers in China are unlikely to see any kind of regulatory framework in the near future. With approximately 60 biosimilars already available in China despite the regulatory lag, that market is estimated to be worth close to $2 billion by 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription